Cytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALS
Out of the analyst recommendations 1 rate Cytokinetics (NASDAQ: CYTK ) stock a Buy, 7 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell. USA stocks are opening higher Tuesday as most industries, including technology and health care companies, start the day with solid gains. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and global copyright & trademark laws.